Lilly's (LLY.US) weight loss drug has a major breakthrough! Research shows that Tirzepatide can significantly reduce the risk of heart failure

One trial showed that Tirzepatide, the active ingredient of Eli Lilly's (LLY.US) blockbuster weight loss drug Zepbound and diabetes treatment drug Mounjaro, could significantly reduce the risk of heart failure deterioration in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.

According to the study, known as "SUMMIT", Tirzepatide reduced the risk of heart failure deterioration in adults with HFpEF and obesity by 38% compared to placebo, and the risk of hospitalization for heart failure by 56%. In addition, patients taking Tirzepatide lost an average of 15.7% of their body weight, while the placebo group lost an average of 2.2%.

Currently, there is no specific treatment for obesity-related HFpEF in the United States. The study was the first to be conducted in patients with obesity-related HFpEF to evaluate the reduction in the risk of heart failure events and improvement in function as primary endpoints. The data showed that Tirzepatide demonstrated statistically significant improvement in both primary endpoints and achieved all key secondary endpoints. In addition, Lilly has submitted Tirzepatide to global regulatory agencies for the treatment of obesity-related HFpEF.